Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers for assessing HIV

a biomarker and hiv technology, applied in the field of new biomarkers for assessing hiv, can solve the problems of inability to predict drug effects, high risk of infection, and inability to cure or effective hiv vaccine,

Inactive Publication Date: 2017-06-29
METABOLOMYCS INC +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides new biomarkers for assessing HIV infection, specifically a combination of metabolites containing acylcarnitine and sphingomyelin, as well as a ratio of certain metabolites to predict immunologic response to antiretroviral therapy and disease progression. These biomarkers can be measured in a blood sample and used for screening, diagnosis, and monitoring of HIV infection in mammals. The use of these biomarkers can help improve the accuracy and early detection of HIV infection.

Problems solved by technology

Therefore they cannot necessarily predict drug effects, toxicological response or disease states at the phenotype level unless functional validation is added.
As the illness progresses, it interferes more and more with the immune system, making the person much more likely to get infections, including opportunistic infections and tumors that do not usually affect people who have working immune systems.
There is currently no cure or effective HIV vaccine.
However, it is becoming increasingly evident that the CD4 count and viral load do not provide a complete picture of the underlying state of the immune system for HIV patients.
However, they are still far from clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for assessing HIV
  • Biomarkers for assessing HIV
  • Biomarkers for assessing HIV

Examples

Experimental program
Comparison scheme
Effect test

examples

[0145]General Information:

[0146]Patients and Methods

[0147]37 random samples were analyzed from HIV-infected patients prospective followed at Sāo Paulo Aids Research Center Cohort (SPARCC). The latter is a recent HIV-infected patient cohort which aim is to study HIV natural history and its progression to AIDS and is well described elsewhere (Kallas BJID 2004).

[0148]SPARCC demographic data, HIV-1 viral load and CD4+ cell count were collected every three months during clinical visits. Samples were analyzed at baseline and one year after follow-up. For immunologic non-respondents and immunologic respondents baseline samples were collected immediately pre-treatment with CD4+ cell counts <350 cells / mm3 and one-year samples were collected exactly at 12 months on treatment visit.

[0149]Controls included 11 non HIV-infected healthy individuals matched by age and sex and because similar metabolic changes induced by viral infections can also be observed in cancer cells (Yu et al 2011) 64 non HI...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
chromatographyaaaaaaaaaa
spectroscopyaaaaaaaaaa
mass spectrometryaaaaaaaaaa
Login to View More

Abstract

The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and / or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and / or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and / or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and / or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patient's therapeutic response to antiretroviral therapy.

Description

TECHNICAL FIELD[0001]The present invention relates to new biomarkers for assessing HIV. In particular, the present invention provides new biomarkers for screening and diagnosing HIV in patients, predicting immunologic response to antiretroviral therapy and prognosis of HIV disease progression, and monitoring HIV disease activity. Moreover, the present invention relates to a method for assessing HIV in a mammalian subject, and to a kit for carrying out the method. More particularly, the present invention is directed to new diagnostic and predictive biomarkers able to identify patients at higher risk to develop incomplete restoration of immune system after antiretroviral treatment as well as rapid progressors patients.BACKGROUND ART[0002]Metabolomics[0003]Metabolomics is a comprehensive quantitative measurement of low molecular weight compounds covering systematically the key metabolites, which represent the whole range of pathways of intermediary metabolism. The capability to analyze...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/92
CPCG01N2800/52G01N33/92G01N33/56988G01N33/6812C12Q1/70G01N33/6893G01N2333/47G01N2405/04G01N2405/08G01N2560/00
Inventor DA SILVA, ISMAEL DALE COTRIM GUERREIROLOTURCO, EDSON GUIMARAESDIAZ, RICOARDO SOUBIEKOAL, THERESE
Owner METABOLOMYCS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com